ERBB2 and breast carcinoma: The latest data presented at the 2021 San Antonio Breast Cancer Symposium (SABCS) disclosed the results of DAISY, a phase II study that assessed the activity of T-DXd in advanced breast cancer (ABC) with different extents of HER2 expression.